Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel therapeutic approaches for treatment of drug-resistant Gram-positive infections

Award Number: R03AI151878
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/12/2020
PERIOD OF PERFORMANCE END DATE: 10/31/2023

Group Awards By:

View Award Description

Novel therapeutic approaches for treatment of drug-resistant Gram-positive infections - Emergence of hospital-associated drug-resistant bacterial infections represents one of the major challenges for the US healthcare system. There is an urgent need for development of new and more effective anti-bacterial agents targeting previously unexplored cellular processes. The goal of this proposal is to find a novel class of biological drugs active against Staphylococcus aureus and pathogenic Enterococci. The bacterial cell wall biogenesis is an established drug target for many existing and novel antibacterial agents. In recent years, lipoteichoic acid biosynthesis pathways emerged as an attractive target for development of new therapeutics. Published data indicate that lipoteichoic acid is required for the growth and survival of Gram-positive bacteria in the host. The experiments in this proposal are designed to generate single domain camelid antibodies (nanobodies) that bind and inactivate extracellular domains of enzymes involved in synthesis and modification of lipoteichoic acid. Upon successful completion of this project we will obtain a number of nanobodies active against S. aureus and Enterococci that would be further validated in in vivo studies. The strategies developed in the proposed study will be also applicable to other medically relevant bacterial pathogens.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Allergy and Infectious Diseases Research	000	2	7/3/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $76,500 )
2022	2022	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Allergy and Infectious Diseases Research	000	2	10/20/2021	NON-COMPETING CONTINUATION	$76,500
														Subtotal = $76,500

Issue Date FY: 2021 ( Subtotal = $76,500 )
2021	2021	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Allergy and Infectious Diseases Research	000	1	11/12/2020	NEW	$76,500
														Subtotal = $76,500

Grand Total All Awards = $153,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel therapeutic approaches for treatment of drug-resistant Gram-positive infections

Award Number: R03AI151878

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/12/2020

PERIOD OF PERFORMANCE END DATE: 10/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer